Actavis Near $64B Deal for Allergan

The transcript discusses major M&A activities in the pharmaceutical sector, focusing on Allegan's defense against hostile takeover bids by Valiant and Ackman. Allegan's concerns include the potential stripping of R&D by Valiant. Legal actions have been taken against Ackman for insider trading. Shareholder dynamics play a crucial role, with meetings and votes influencing the outcome. Alternative strategies, such as acquiring Zoetis, are considered. The financial implications for key players like Blackman and Valiant are significant, with potential profits regardless of the outcome.

What potential alternative acquisition is mentioned for Valiant?

What role does Bill Ackman play in the context of the Allegan deal?